Immunor

Immunor AS is a Norwegian biotechnology company specializing in the development of peptide-based vaccines and immunotherapies. The company utilizes its proprietary Cell Penetrating Selective Peptide Vaccine Platform (CPSPVP) to design precise and safe vaccines for infectious diseases, oncology, and autoimmune conditions. Its lead programs include Vacc-4x, a therapeutic HIV vaccine that has demonstrated significant viral load reduction in Phase 2 trials, and Vacc-Diab1 for Type 1 Diabetes. Immunor is also advancing candidates for glioblastoma and diabetic neuropathy. The company's approach combines computational guided discovery with a focus on targeting conserved viral regions to achieve functional cures.